KRAS and lung cancer: Sasaki et al.[36] reported that GLUT-1 overexpression evaluated by immunohistochemistry was significantly correlated with EFGR or KRAS mutation status, with overexpression in 18 (24%) of 76 EGFR m+ lung cancers and 20 (67%) of 30 KRAS m+ lung cancers.